title: Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study.
abstract: Ovarian cancer is a life-threatening diagnosis which poses multiple challenges. The purpose of this study is to describe the quality of life (QOL) concerns and survivorship sequelae of long-term (>5 yr) early-stage ovarian cancer survivors accrued through the clinical cooperative Gynecologic Oncology Group. Forty-nine ovarian cancer survivors with a mean age at diagnosis of 55.9 yr (range 30-76) completed a telephone interview assessing QOL, psychosocial status, sexual functioning and late-effects of treatment. Results indicate that this disease-free early-stage sample enjoys a good QOL, with physical, emotional, and social well-being comparable to other survivors and same-aged noncancer cohorts. However, 20% of survivors indicated the presence of long-term treatment side effects, with a subset reporting problems related to abdominal and gynecologic symptoms, and neurotoxicity. Spiritual well-being was significantly positively associated with personal growth and mental health, and negatively associated with a declining health status. Lingering psychological survivorship sequelae included fear of follow-up diagnostic tests and fear of recurrence. Forty-three percent of respondents expressed that they would likely participate in a counseling program today to discuss psychosocial issues raised by having had ovarian cancer, and 56% stated that they would have attended a support program during the initial treatment if it had been offered. This information provides some insight into the complex survivorship relationships between quality of life, long-term physical and sexual sequelae, and factors of resilience and growth which appear to promote a sense of well-being as a result of the cancer experience.
authors.affiliation: Epidemiology Division, College of Medicine, University of California, Irvine 92697-7555, USA.
authors.forename: Lari B
authors.initials: LB
authors.lastname: Wenzel
authors.forename: James P
authors.initials: JP
authors.lastname: Donnelly
authors.forename: Jeffery M
authors.initials: JM
authors.lastname: Fowler
authors.forename: Rana
authors.initials: R
authors.lastname: Habbal
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Taylor
authors.forename: Noreen
authors.initials: N
authors.lastname: Aziz
authors.forename: David
authors.initials: D
authors.lastname: Cella
mesh_terms: D000223:Adaptation, Psychological; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001918:Brachytherapy / Q000523:psychology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005239:Fear; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000523:psychology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000523:psychology* / Q000532:radiotherapy; D010555:Personality Inventory; D010761:Phosphorus Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D012803:Sick Role; D013315:Stress, Psychological / Q000150:complications*; D017741:Survivors / Q000523:psychology*
chemical_list: D010761:Phosphorus Radioisotopes; D003520:Cyclophosphamide; D002945:Cisplatin